STOCK TITAN

Option grant gives LeonaBio (LONA) director 56,000 shares at $9.63

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LeonaBio, Inc. director Callori Fred received a grant of stock options covering 56,000 shares of common stock. The options have an exercise price of $9.63 per share and expire on May 4, 2036. All 56,000 options are held directly after this award.

The options are scheduled to vest in equal installments monthly over 36 months from the grant date, as long as the director continues to serve as a service provider under LeonaBio’s 2026 Equity Incentive Plan.

Positive

  • None.

Negative

  • None.
Insider Callori Fred
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 56,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 56,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 56,000 options Stock Option (Right to Buy) awarded to director
Exercise price $9.63 per share Conversion or exercise price for the options
Expiration date May 4, 2036 Option term end date
Underlying shares 56,000 shares Common stock underlying the options
Vesting period 36 months Monthly vesting schedule from grant date
Post-transaction derivative holdings 56,000 options Total options held directly after grant
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
vest financial
"shares subject to the option are scheduled to vest monthly over a term of 36 months"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Equity Incentive Plan financial
"as defined in the Issuer's 2026 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
derivative financial
"transaction_type: derivative"
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Callori Fred

(Last)(First)(Middle)
C/O LEONABIO, INC.
18706 NORTH CREEK PARKWAY, SUITE 104

(Street)
BOTHELL WASHINGTON 98011

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$9.6305/05/2026A56,000 (1)05/04/2036Common Stock56,000$056,000D
Explanation of Responses:
1. The shares subject to the option are scheduled to vest monthly over a term of 36 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
/s/ Mark Worthington, Attorney in fact for Fred P. Callori05/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did LeonaBio (LONA) director Callori Fred report in this Form 4?

Callori Fred reported receiving a grant of stock options for 56,000 shares of LeonaBio common stock. These options were awarded at an exercise price of $9.63 per share and represent compensation rather than an open-market stock purchase or sale.

How many LeonaBio (LONA) options did Callori Fred receive and at what price?

Callori Fred received stock options covering 56,000 shares of LeonaBio common stock. The options carry an exercise price of $9.63 per share, meaning this is the price at which the director can buy shares if the options are exercised.

When do Callori Fred’s LeonaBio (LONA) stock options vest?

The 56,000 LeonaBio stock options are scheduled to vest monthly over 36 months following the grant. Vesting occurs on each monthly anniversary of the grant date, provided Callori Fred continues as a service provider under the company’s 2026 Equity Incentive Plan.

When do the LeonaBio (LONA) options granted to Callori Fred expire?

The stock options granted to Callori Fred are scheduled to expire on May 4, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to purchase LeonaBio common shares at the stated exercise price.

Is Callori Fred’s Form 4 transaction a market buy or sell of LeonaBio (LONA) shares?

The Form 4 shows a grant of stock options, not a market purchase or sale of existing shares. It is classified as a grant, award, or other acquisition of derivative securities provided as compensation, rather than an open-market trading transaction.

How many LeonaBio (LONA) options does Callori Fred hold after this grant?

Following this reported transaction, Callori Fred holds 56,000 stock options directly. These options each relate to one share of LeonaBio common stock and are subject to the vesting and expiration terms described in the company’s equity incentive plan.